Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","amount":"$3.3 million","upfrontCash":"Undisclosed","newsHeadline":"Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for a New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000309

    Menu

    Prestwick3_000309

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Fosun Pharmaceutical

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for a New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Impro...

              Details:

              The financing will be used for a clinical phase III trial for a fixed-dose combination of artemether-lumefantrine-amodiaquine drug (three existing antimalarial drugs already developed, marketed and sold) against malaria.

              Lead Product(s): Artemether,Lumefantrine,Amodiaquine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: GHIT Fund

              Deal Size: $3.3 million Upfront Cash: Undisclosed

              Deal Type: Financing December 13, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY